期刊文献+

肝硬化钠代谢紊乱与肝功能Child分级276例分析 被引量:2

The Natrium of Hepatocirrhosis is Turbulenced Metabolize and Liver Function C Hild Classification's 276 Caseload Anlayze
暂未订购
导出
摘要 目的:探讨肝硬化失代偿期患者血清钠代谢变化与肝功能Child分级的相关性。方法:对276例肝硬化失代偿期患者行血钠检查及肝功能Child分级。结果:患者发生低钠血症的程度随肝功能分级的不同而有明显差异,84例低钠血症肝功能A级(ChildA),114例低钠血症肝功能B级(ChildB),78例低钠血症肝功能C级(ChildC),肝功能ChildB级,ChildC级与ChildA级比较,发生低钠血症的例数按四方表格X2检验有非常显著差异,P<0·01,肝功能ChildB级与ChildC级比较,差异无显著性。结论:肝硬化失代偿期钠代谢紊乱变化与肝功能Child分级正相关。
出处 《华西医学》 CAS 2006年第1期119-120,共2页 West China Medical Journal
  • 相关文献

参考文献8

  • 1叶任高.内科学[M].第五版[M].北京:人民卫生出版社,2000.159-169.
  • 2徐晓光,蔡洪培.肝硬化低钠血症研究进展[J].中华消化杂志,2002,22(9):560-562. 被引量:95
  • 3Jalan R Hayespc,Sodium handling inpatients with Compenstateed cirrhosis is dependent on the severity of liver disease ahd portal Pressure Gut[J].2000,46:527-533.
  • 4陈灏珠.实用内科学(第11版)[M].北京:人民卫生出版社,2001.1785.
  • 5Gines Paquaretic.aquaretic agents:a nen potential treatment of dilutional hyponatremia in cirrhosis Jhepotol[J].1996,24:506-512.
  • 6Gulbergv.Mouers,Henriksen JH,et al.increased renal proudcion of C-type nateiuretic peptde(CNP)in patients with cirrhosis and functional renal failure[J].Get,2000,47:852-657.
  • 7Borroni G,Clincal relevance of hyponafraemia for the hospital outcome of cirrhotic patients[J].Digliver Dis,2000,32:605-610.
  • 8赵春华,杨道锋,田德英.肝硬变Child-Pugh肝功能分级与电解质紊乱的关系[J].中西医结合肝病杂志,1999,9(3):5-7. 被引量:11

二级参考文献14

  • 1Decaux G.Difference is solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985[].Journal of Laboratory and Clinical Medicine.2001
  • 2Gadano A,Moreau R,Pessione F,et al.Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis[].Journal of Hepatology.2000
  • 3Gines P,Jimenez W.Aquaretic agent: a new potential treatment of dilutional hyponatremia in cirrhosis[].Journal of Hepatology.1996
  • 4Gines P,Jimenez W.Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis[].Journal of Hepatology.1996
  • 5Bosch-Marce M,Jimenez W,Angeli P,et al.Aquaretic effect of the kappa-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention[].Gastroenterology.1995
  • 6Bosch-Marce M,Poo JL,Jimenez W,et al.Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention[].Journal of Pharmacology and Experimental Therapeutics.1999
  • 7Borroni G,Maggi A,Sangiovanni A,et al.Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients[].Digestive and Liver Disease.2000
  • 8Serradeil-Le-Gal C.Nonpeptide antagonists for vasopressin receptors.Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist[].Advances in Experimental Medicine and Biology.1998
  • 9Yamamura Y,Ogawa H,Yamashita H,et al.Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist[].British Journal of Pharmacology.1992
  • 10Gulberg V,Moller S,Henriksen JH,et al.Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure[].Gut.2000

共引文献562

同被引文献7

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部